基于Nrf2/HO-1信号通路探讨四逆散对胆汁淤积性肝炎大鼠氧化应激反应的影响

被引:11
作者
曹丹 [1 ,2 ]
陈祺 [1 ]
陈小橹 [1 ]
陈林珍 [1 ]
王海燕 [3 ]
郝巨辉 [4 ]
张威 [5 ]
马志强 [1 ]
机构
[1] 北京中医药大学中药品质评价北京市重点实验室
[2] 北京同仁堂科技发展股份有限公司制药厂
[3] 大连市妇女儿童医疗中心(集团),生殖与遗传医学中心
[4] 北京中医药大学中药学院
[5] 哈尔滨医科大学附属第一医院
关键词
四逆散; 胆汁淤积性肝炎; 氧化应激; 核因子E2相关因子2(Nrf2); 血红素氧合酶-1(HO-1);
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
100806 [中药药理学];
摘要
目的:基于核因子E2相关因子2(Nrf2)/血红素氧合酶-1(HO-1)信号通路探讨四逆散对胆汁淤积性肝炎大鼠肝脏氧化应激损伤的影响及其作用机制。方法:30只6周雄性SD大鼠,随机分为正常组、模型组、四逆散低、高剂量组(2.5、5.0 g·kg-1)、熊去氧胆酸(UDCA,63 mg·kg-1)组,每组6只。各组大鼠连续给药7 d,第5天除对照组给予10 m L·kg-1橄榄油外,其余各组均给予80 mg·kg-1的α-萘异硫氰酸酯(ANIT);采用酶联免疫吸附测定法(ELISA)检测血清中胆汁淤积相关生化指标水平,以及肝组织中抗氧化因子的含量;通过苏木素-伊红(HE)染色观察肝组织病理变化;采用实时荧光定量聚合酶链式反应(Real-time PCR)和蛋白免疫印迹法(Western blot)检测肝组织中Nrf2、HO-1和醌氧化还原酶1(NQO1) mRNA与蛋白的相对表达量。结果:与正常组比较,模型组血清各胆汁淤积生化指标水平、肝组织中抗氧化应激因子含量均显著升高(P<0.01),模型组肝细胞排列紊乱、门管区有明显的瘀血性坏死,炎性细胞浸润,小叶间胆管破坏等病理学改变;模型组大鼠肝组织中Nrf2、HO-1和NQO1 mRNA与蛋白相对表达水平均明显下调(P<0.05,P<0.01)。与模型组比较,四逆散高剂量组的血清各胆汁淤积生化指标水平、肝组织中抗氧化应激因子含量均显著降低(P<0.01);肝病理损伤较模型组有明显改善,表现为坏死面积明显缩小,炎性细胞浸润显著减少,小叶间静脉有少量瘀血;肝组织中Nrf2、HO-1和NQO1 mRNA与蛋白相对表达水平均明显上调(P<0.05,P<0.01)。结论:四逆散能显著改善肝内胆汁淤积性肝炎大鼠肝损伤,其机制可能与Nrf2/HO-1信号通路介导的抑制氧化应激反应有关。
引用
收藏
页数:7
相关论文
共 28 条
[21]
基于慢性不可预知温和应激大鼠模型的“肝主疏泄”生物学基础研究 [D]. 
李君玲 .
北京中医药大学,
2016
[22]
Predictors of Serious Adverse Events and Non-response in Cirrhotic Patients With Primary Biliary Cholangitis treated with Obeticholic Acid.[J] De Vincentis Antonio;D'Amato Daphne;Cristoferi Laura;Gerussi Alessio;Malinverno Federica;Lleo Ana;Colapietro Francesca;Marra Fabio;Galli Andrea;Fiorini Cecilia;Coco Barbara;Brunetto Maurizia;Niro Grazia Anna;Cotugno Rosa;Saitta Carlo;Cozzolongo Raffaele;Losito Francesco;Giannini Edoardo Giovanni;Labanca Sara;Marzioni Marco;Marconi Giulia;Morgando Anna;Pel
[23]
Notoginsenoside R1 Protects Against High Glucose-Induced Cell Injury Through AMPK/Nrf2 and Downstream HO-1 Signaling[J] Du Fawang;Huang Huiling;Cao Yalin;Ran Yan;Wu Qiang;Chen Baolin Frontiers in Cell and Developmental Biology 2021,
[24]
A Network Pharmacology Study of the Molecular Mechanisms of Hypericum japonicum in the Treatment of Cholestatic Hepatitis with Validation in an Alpha-Naphthylisothiocyanate (ANIT) Hepatotoxicity Rat Model[J] Feng Sen Ling;Zhang Jing;Jin Hongliu;Zhu Wen Ting;Yuan Zhongwen Medical Science Monitor 2021,
[25]
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.[J] Kowdley Kris V;Luketic Velimir;Chapman Roger;Hirschfield Gideon M;Poupon Raoul;Schramm Christoph;Vincent Catherine;Rust Christian;Parés Albert;Mason Andrew;Marschall Hanns-Ulrich;Shapiro David;Adorini Luciano;Sciacca Cathi;Beecher-Jones Tessa;Böhm Olaf;Pencek Richard;Jones David Hepatology (Baltimore; Md.) 2018,
[26]
Cost-Effectiveness Analysis of Obeticholic Acid For The Treatment of Primary Biliary Cholangitis (PBC) Patients With Inadequate Response or Intolerance To Ursodeoxycholic Acid (UDCA) In France[J] L Baschet;S Bourguignon;A Tison Value in Health 2017,
[27]
Obeticholic Acid: First Global Approval.[J] Markham A;Keam Susan J Drugs 2016,
[28]
Paeonia lactiflora Pall. protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway[J] Ma X;Zhao Y;Zhu Y;Chen Z;Wang J;Li R;Chen C;Wei S;Li J;Liu B;Wang R;Li Y;Wang L;Xiao X Drug Design; Development and Therapy 2015,